Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TANDEM: tropifexor and cenicriviroc in adults with NASH and liver fibrosis
MOH_2018-08-13_002369Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tropifexor and cenicriviroc in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (4 arms), sponsored by Novartis. Started Jun 2018; status: completed.
02
Drugs
tropifexorcenicriviroc
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on MOH_2018-08-13_002369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-13_002369.